MYL7 (myosin light chain 7) is a cardiac-specific protein that plays a critical role in heart contraction and ventricular function. As a component of the myosin complex, MYL7 is essential for normal cardiac muscle contractility and is preferentially expressed in atrial cardiomyocytes 1. The protein functions through calcium ion binding and interaction within myofibrils to facilitate cardiac muscle tissue development and contraction [GO annotations]. MYL7 has significant clinical relevance in multiple cardiac pathologies. Downregulation of MYL7 contributes to reduced cardiac contractility in arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by desmosomal protein deficiency, as demonstrated by restoration of heart function following MYL7 augmentation in disease models 2. MYL7 is also downregulated in dilated cardiomyopathy with right ventricular systolic dysfunction 2. Additionally, MYL7 serves as a validated marker for identifying and studying iPSC-derived cardiomyocytes 34 and is among key genes dysregulated in cardiac hypertrophy across different patient populations 5. Beyond cardiac tissue, MYL7-specific autoantibodies have been detected in COVID-19 patients with neurological complications 6, suggesting broader pathological relevance. These findings establish MYL7 as both a critical structural-functional component of cardiac muscle and a potential therapeutic target for inherited and acquired cardiomyopathies.